CURE vs SPY
Direxion Daily Healthcare Bull 3X ETF vs State Street SPDR S&P 500 ETF Trust
Which is better, CURE or SPY?
Multi Alternative against Large Cap Blend.
SPY has a lower expense ratio. CURE led over 1Y and the full window, SPY over 3Y and 5Y. SPY is less concentrated, with 38.2% of the fund in its ten largest positions against 59.8%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | CURE | SPY |
|---|---|---|
| Expense Ratio | 0.93% | 0.09%Best |
| AUM | $164M | $823.2B |
| Dividend Yield | 0.98% | 0.99% |
| Holdings | 134 | 1,515 |
| YTD Return | +25.93%Best | +13.53% |
| 1Y Return | +60.78%Best | +17.47% |
| 3Y Return (annualized) | +16.35% | +22.36%Best |
| 5Y Return (annualized) | +6.86% | +13.21%Best |
| Volatility (annualized) | 41.8% | 14.3%Best |
| Max Drawdown | -69.2% | -34.1%Best |
| $10,000 over 5 years | $13,934 | $18,596Best |
| Top 10 Weight | 59.8% | 38.2%Best |
| Fund Family | Direxion Shares ETF Trust | State Street Investment Management |
| Category | Alternative | Equity |
| Style | Multi Alternative | Large Cap Blend |
| Inception | Jun 15, 2011 | Jan 22, 1993 |
Volatility and max drawdown are measured over the window both funds cover: Jun 15, 2011 to Oct 14, 2026 (15.3 years).
CURE vs SPY growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 15.3 years both funds cover.
CURE vs SPY Performance
Direxion Daily Healthcare Bull 3X ETF (CURE) is an ETF from Direxion Shares ETF Trust and State Street SPDR S&P 500 ETF Trust (SPY) is an ETF from State Street Investment Management. Over the past year CURE returned +60.78% while SPY returned +17.47%. Year to date, CURE is up 25.93% versus a gain of 13.53% for SPY.
Over three years, CURE compounded at +16.35% per year against +22.36% for SPY; over five years the annualized figures are +6.86% and +13.21% respectively. Across the full 15-year window we track, CURE has the edge at +24.84% annualized vs +13.03%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
CURE has been the more volatile fund, with annualized monthly volatility of 41.8% compared with 14.3% for SPY. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -69.2% for CURE and -34.1% for SPY. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.73. They usually move together, but the gap leaves some room for diversification.
Fees and Cost Over Time
CURE charges 0.93% per year while SPY charges 0.09%. On a $10,000 position that is $93 vs $9 annually, a gap of $84 per year that compounds over a long holding period. On income, CURE currently yields 0.98% against 0.99% for SPY.
Holdings Overlap
37.2% of CURE's money is in holdings SPY also owns. 0.5% of SPY's money is in holdings CURE also owns.
The two portfolios partly overlap.
6 positions in common, counted across the 49 positions we hold weights for in CURE and 504 in SPY, against full books of 134 and 1,515.
What only one of them owns
Our book lists 490 positions for SPY that do not appear in our book for CURE (98.5% of the fund), and 30 for CURE that do not appear in SPY (45.2%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
37.2% of CURE is already inside SPY.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, CURE or SPY?
CURE has an expense ratio of 0.93% while SPY charges 0.09%. SPY is the cheaper option, by $84 a year on a $10,000 investment.
Which performed better, CURE or SPY?
Over the past year CURE returned +60.78% vs +17.47% for SPY, so CURE leads on 1-year performance. Over the longest common window we track (15 years), CURE annualized +24.84% vs +13.03% for SPY. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, CURE or SPY?
CURE has been the more volatile fund at 41.8% annualized versus 14.3% for SPY. Worst drawdown: CURE -69.2% vs SPY -34.1%.
Should I hold both CURE and SPY?
CURE and SPY have a monthly-return correlation of 0.73, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between CURE and SPY?
37.2% of CURE's money is in holdings SPY also owns. 0.5% of SPY's is in holdings CURE also owns. They hold 6 positions in common, counted across the 49 positions we hold weights for in CURE and 504 in SPY.
Which pays a higher dividend, CURE or SPY?
CURE yields 0.98% while SPY yields 0.99%, so SPY currently pays the higher dividend yield.
Is SPY better than CURE?
SPY has a lower expense ratio. CURE led over 1Y and the full window, SPY over 3Y and 5Y. SPY is less concentrated, with 38.2% of the fund in its ten largest positions against 59.8%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.